Key Highlights
- Jabil (NYSE: JBL) has acquired Pharmaceutics International, Inc. (Pii) to expand its pharmaceutical manufacturing capabilities.
- The acquisition adds Pii’s expertise in aseptic filling, lyophilization, and oral solid dose manufacturing to Jabil’s portfolio.
- Pii’s 360,000+ sq. ft. GMP facilities in Hunt Valley, Maryland, will integrate into Jabil’s global infrastructure and supply chain.
- Strengthens Jabil’s parenteral drug delivery solutions, supporting auto-injectors, pen injectors, inhalers, and on-body pumps.
- Pii’s 300+ team members join Jabil, enhancing end-to-end support for pharmaceutical customers.
Source: Business Wire
Notable Quotes
“Jabil is very pleased to announce this acquisition. With our shared commitment to creating the best solutions possible for patients around the world, we believe the addition of Pii’s capabilities, supported by over 300 team members, is a perfect fit for Jabil and our customers.” — James O’Gorman, Vice President, Pharmaceutical Solutions at Jabil
“As the pace of healthcare innovation accelerates, pharmaceutical companies need partners who can help them scale rapidly with a focus on quality and safety. Jabil and Pii’s combined capabilities can provide end-to-end support for pharmaceutical customers, offering one safe, trusted pair of hands to simplify their entire supply chain.” — Mike Mahaz, SVP, Global Business Units, Healthcare at Jabil
“This acquisition marks an exciting new chapter for Pii. We look forward to leveraging Jabil’s extensive expertise to accelerate our mission of delivering best-in-class drug development and manufacturing solutions to our customers and ultimately the patients we serve.” — John Fowler, President & CEO at Pii
Why This Matters
The acquisition of Pharmaceutics International, Inc. (Pii) marks a strategic expansion of Jabil’s Pharmaceutical Solutions portfolio, reinforcing its end-to-end drug development and manufacturing capabilities. With the increasing demand for safe, scalable, and high-quality pharmaceutical manufacturing, this move positions Jabil as a key player in the Contract Development and Manufacturing Organization (CDMO) market. By leveraging Pii’s scientific expertise, cutting-edge manufacturing facilities, and Jabil’s global supply chain, this integration aims to drive efficiency, innovation, and growth for pharmaceutical partners worldwide.
